SLFN11 EXPRESSION

CI-VAR-00000916Explore in graph →CIViC 366

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Ewing Sarcoma1
SLFN11 EXPRESSION	Niraparib + TemozolomideCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID5884 SLFN11 is an ETS transcription factor response gene and a predictive marker for therapeutic response to topoisomerase I inhibitors and temozolomide-PARP inhibitor combinations in ETS-activated cancers… (full text at CIViC) PMID 25779942 · Tang et al., 2015 · Open in CIViC	civic
Lung Small Cell Carcinoma1
SLFN11 EXPRESSION	Talazoparib + TemozolomideCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID5883 SLFN11 is a relevant predictive biomarker of sensitivity to PARP inhibitor monotherapy in SCLC as well as combinatorial therapy with TMZ.

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Colorectal Neoplasm1
SLFN11 EXPRESSION	7-Ethyl-10-Hydroxycamptothecin	Predictive	D	Supports Sensitivity Response	2	accepted	EID870 In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan). PMID 25089570 · Tian et al., 2014 · Open in CIViC	civic